MMEDF, Where’s the moat?

Thesis

Mindmed on the back of the ‘shroom-boom’ and a star investor in Kevin O’Leary has grabbed headlines as the next leader in mental health. However the firm’s questionable IP, delayed up-listing on the NASDAQ and recent insider selling, raise questions on the companies true ability to capitalise on a market with significant unmet need. In this article we will review the competitive landscape with Mindmed’s addressable markets.

The company

Mind Medicine (MindMed) Inc (NEO: MMED and OTCQB: OTCQB:MMEDF) is a small-cap pharmaceutical…